Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report

被引：387

作者：

Piekarz, RL

Robey, R

Sandor, V

Bakke, S

Wilson, WH

Dahmoush, L

Kingma, DM

Turner, ML

Altemus, R

Bates, SE

机构：

[1] NCI, Med Branch, Pathol Lab, Ctr Canc Res,NIH, Bethesda, MD 20892 USA

[2] NCI, Dermatol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

[3] NCI, Radiat Oncol Branch, Ctr Canc Res, NIH, Bethesda, MD 20892 USA

来源：

BLOOD | 2001年 / 98卷 / 09期

关键词：

D O I：

10.1182/blood.V98.9.2865

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide conducted at the National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete response. Sezary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma. (C) 2001 by The American Society of Hematology.

引用

页码：2865 / 2868

页数：4

共 21 条

[1] SYSTEMIC THERAPY OF CUTANEOUS T-CELL LYMPHOMAS (MYCOSIS-FUNGOIDES AND THE SEZARY-SYNDROME) [J].